Thrombohemorrhagic complications of myeloproliferative disorders

Blood Reviews

Volumn 24, Issue 6, 2010, Pages 227-232

  Papadakis, Emmanouil ^a   Hoffman, Ron ^b   Brenner, Benjamin ^b  

^a Pappagergiou Hospital   (Greece)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; HYDROXYUREA; INTERFERON; JANUS KINASE 2; PROTON PUMP INHIBITOR;

ARTERY THROMBOSIS; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; ERYTHROCYTOSIS; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERVISCOSITY SYNDROME; LEUKOCYTE ACTIVATION; LEUKOCYTOSIS; LOW DRUG DOSE; MICROANGIOPATHY; MICROCIRCULATION; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RETINA ARTERY THROMBOSIS; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE DISORDER; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOPHILIA; THROMBOSIS; TREATMENT DURATION; VEIN THROMBOSIS;

ANTINEOPLASTIC AGENTS; HUMANS; MYELOPROLIFERATIVE DISORDERS; THROMBOSIS;

EID: 78149470436     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2010.08.002     Document Type: Article

References (80)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951, 6:372-375.
2. Spivak J.L. The chronic Myeloproliferative Disorders: clonality and clinical heterogeneity. Semin Hem 2004, 41:1-5.
3. Elliott M.A., Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2004, 128:275-290.
4. Gruppo Italiano Studio Policitemia Polycythemia vera: the natural history of 1213 patients followed for 20years. Ann Intern Med 1995, 123:656-664.
5. Reisner S.A., Rinkevich D., Markiewicz W., Tatarsky I., Brenner B. Cardiac involvement in patients with myeloproliferative disorders. Am J Med 1992, 93:498-504.
6. Cortelazzo S., Viero P., Finazzi G., D'Emilio A., Rodeghiero F., Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990, 8:556-562.
7. Besses C., Cervantes F., Pereira A., Florensa L., Sole F., Hernandez-Boluda J.C., et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999, 13:150-154.
8. Passamonti F., Rumi E., Pungolino E., Malabarba L., Bertazzoni P., Valentini M., et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004, 117:755-761.
9. Wolanskyj A.P., Schwager S.M., McClure R.F., Larson D.R., Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, longterm complication rates, and prognostic factors. Mayo Clin Proc 2006, 81:159-166.
10. Barbui T., Carobbio A, Cervantes F, Vannucchi A, Guglielmelli P Antonioli E, Alvarez-Larran A, Rambaldi A, Finazzi G and Barosi G Thrombosis in primary myelofibrosis: incidence and risk factors. Blood First Edition Paper, prepublished online November 20, 2009; DOI doi:10.1182/blood-2009-08-238956.
11. Landolfi R., Rocca B., Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Crit Rev Onc-Hem 1995, 20:203-222.
12. Schafer A.I. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984, 64:1-12.
13. Fenaux P., Simon M., Caulier M.T., Lai J.L., Goudemand J., Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990, 66:549-556.
14. Colombi M., Radaelli F., Zocchi L., Maiolo A.T. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991, 67:2926-2930.
15. Jensen M.K., de Nully Brown P., Nielsen O.J., Hasselbalch H.C. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2000, 65:132-139.
16. Chim C.S., Kwong Y.L., Lie A.K., et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 2005, 165:2651-2658.
17. Campbell P.J., Scott L.M., Buck G., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK-2 V617F mutation status: a prospective study. Lancet 2005, 366:1945-1953.
18. Carobbio A., Finazzi G., Guerini V., Spinelli O., Delaini F., Marchioli R., et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and JAK-2 mutation status. Blood 2007, 109(6):2310-2313.
19. De Stefano V. et al, for the GIMEMA CMD-Working Party Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008;93(3) 372-381.
20. Passamonti F., Brusamolino E., Lazzarino M., et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica 2000, 85:1011-1018.
21. Marchioli R., Finazzi G., Landolfi R., et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005, 23:2224-2232.
22. Anger B.R., Seifried E., Scheppach J., Heimpel H. Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr 1989, 67:818-825.
23. Najean Y., Mugnier P., Dresch C., Rain J.D. Polycytemia vera in young people: an analysis of 58 cases diagnosed before 40year. Br J Hem 1987, 67:285-291.
24. Perea G., Remancha A., Besses C., Jimenez M., et al. Is polycythemia vera a serious disease in young adults?. Haematologica 2001, 86:543-544.
25. Denniger M.H., Chait Y., Casadevall N., Hillaire S., et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000, 31:587-591.
26. Primignani M., Barosi G., Bergamaschi G., et al. Role of the JAK-2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006, 44:1528-1534.
27. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK-2 V617F Era. ASH Education Book 2006, 240-245. 2006.
28. Michiels J.J., Berneman Z., Bockstaele D.V., van der Planken M., De Raeve H., Schroyens W. Clinical and laboratory features, pathology of platelet-mediated thrombosis and bleeding complications and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006, 32:174-207.
29. Michiels J.J., Abels J., Steketee J., Van Vliet H.H., et al. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 1985, 102:466-471.
30. Michiels J.J. Erythromelalgia and thrombocythemia: a disease of platelet prostaglandin metabolism-thesis. Rotterdam, 1981. Semin Thromb Haemost 1997, 23:335-338.
31. Van Genderen P.J., Michiels J.J., Van Strik R., Lindemans J., et al. Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb Haemost 1995, 73:210-214.
32. Van Genderen P.J., Mulder P.G., Waleboer M., Van De Moesdijk D., et al. Prevention and treatment of thrombotic complications in essential thrombocythemia: efficacy and safety of aspirin. Br J Haematol 1997, 97:179-184.
33. Kurzrock R., Cohen P.R. Erythromelalgia: review of clinical characteristics and pathophysiology. Am J Med 1991, 91:416-422.
34. Zucker S., Mielke C.H. Classification of thrombocytosis based on platelet function test: correlation with hemorrhagic and thrombotic complications. J Lab Clin Med 1972, 80:385-394.
35. Van Genderen P.J., Michiels J.J. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Méd 1994, 23:73-77.
36. Wehmeier A., Daum I., Jamin H., Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hemtol 1991, 63:101-106.
37. Menon K.V., Shah V., Kamath P.S. The Budd-Chiari syndrome. N Engl J Med 2004, 350:578-585.
38. Tartaglia A.P., Goldberg J.D., Berk P.D., Wasserman L.R. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 1986, 23:172-176.
39. Pearson T.C., Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythemia. Lancet 1978, 2:1219-1222.
40. Kwaan H.C., Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost 2003, 29:451-458.
41. Huang P.Y., Hellums J.D. Aggregation and disaggregation kinetics of human blood platelets: the disaggregation under shear stress of platelet aggregates. Biophys J 1993, 65:354-361.
42. Landolfi R., Ciabattoni G., Patrignani P., Castellana M.A., Pogliani E., Bizzi B., et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992, 80:1965-1971.
43. Turitto V.T., Weiss H.J. Red blood cells: their dual role in thrombus formation. Science 1980, 207:541-543.
44. Yedgar S., Koshkaryev A., Barshtein G. The red blood cell in vascular occlusion. Pathophysiol Haemost Thromb 2002, 32:263-268.
45. Pearson M.J., Lipowsky H.H. Influence of erythrocyte aggregation on leukocyte margination in postcapillary venules of rat mesentery. Am J Physiol Heart Circ Physiol 2000, 279:1460-1471.
46. Cortellazzo S., Finazzi G., Ruggeri M., Vestri O., et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995, 332:1132-1136.
47. Buss D.H., Stuart J.J., Lipscomb G.E. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am J Hematol 1985, 20:365-372.
48. Michiels J.J., Budde U., van der Planken M., van Vliet H.H., Schroyens W., Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Bailliere's Best Practice in Clinical Haematology 2001, 14:401-436.
49. van Genderen P.J., Budde U., Michiels J.J., van Strik R., van Vliet H.H. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J of Haem 1996, 93:962-965.
50. van Genderen P.J., Prins F.J., Lucas I.S., van de Moesdijk D., van Vliet H.H., van Strik R., et al. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. Br J of Haem 1997, 99:832-836.
51. Favaloro E.J. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thr and Haem 2000, 83:127-135.
52. Budde U., Scharf R.E., Franke P., Hartmann-Budde K., Dent J., Ruggeri Z.M. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993, 82:1749-1757.
53. Wu K.K. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med 1978, 88:711.
54. Valles J., Santos M.T., Aznar J., Martinez M., Moscardo A., Pinon M., et al. Platelet-erythrocyte interactions enhance alpha (IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo. Blood 2002, 99:3978-3984.
55. Jensen M.K., de Nully Brown P., Lund B.V., Nielsen O., Hasselbalch H.C. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haem 2000, 110:116-124.
56. Carobbio A., Antonioli E., Guglielmelli P., Vannucchi A.M., Delaini F., Guerini V., et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008, 26:2732-2736.
57. Carobbio A., Finazzi G., Guerini V., Spinelli O., Delaini F., Marchioli R., et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and JAK-2 mutation status. Blood 2007, 109:2310-2313.
58. Alvarez-Larran A., Cervantes F., Bellosillo B., Giralt M., Julia A., Hernandez-Boluda J.C., et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 2007, 21:1218-1223.
59. Falanga A., Marchetti M., Evangelista V., Vignoli A., et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000, 96:4261-4266.
60. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK-2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
61. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK-2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
62. Kralovics R., Passamonti F., Buser A.S., et al. A gain-off function mutation of JAK-2 in myeloproliferative disorders. NEJM 2005, 352:1779-1790.
63. Zhao R., Xing S., Li Z., et al. Identification of an acquired JAK-2 mutation in polycythemia vera. J Biol Chem 2005, 280:22788-22792.
64. Kubota Y., Tanaka T., Ohnishi H., Kitanaka A., Okutani Y., Taminato T., et al. Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation. Leukemia 2004, 18:1127-1137.
65. Falanga A., Marchetti M., Vignoli A., Balducci D., Russo L., Guerini V., et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007, 35:702-711.
66. Chong A.Y., Blann A.D., Patel J., Freestone B., Hughes E., Lip G.Y. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 2004, 110:1794-1798.
67. Marchetti M., Castoldi E., Marchetti M., Castoldi E., Spronk H.M., van Oerle R., et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood Aug 15 2008, 112(10):4061-4068.
68. Landolfi R., Di Gennaro L., Barbui T., et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007, 109(6):2446-2452.
69. Jantunen R., Juvonen E., Ikkala E., Oksanen K., Anttila P., Ruutu T. The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Ann Hematol 2001, 80:74-78.
70. Afshar-Kharghan V.L.A., Gray L., Padilla A., Borthakur G., Roberts S., Pruthi R., et al. Hemostatic gene polymorphisms and the prevalence of thrombohemorrhagic complications in polycythemia vera and essential thrombocythemia. Blood 2001, 98:471a.
71. Dicato M.A., Schroell B., Berchem G.J. V Leiden mutations, prothrombin and methylene-tetrahydrofolate reductase are not risk factors for thromboembolic disease in essential thrombocythemia. Blood 1999, 94:111a.
72. Ruggeri M., Gisslinger H., Tosetto A., Rintelen C., Mannhalter C., Pabinger I., et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002, 71:1-6.
73. Amitrano L., Guardascione M.A., Ames P.R., Margaglione M., Antinolfi I., Iannaccone L., et al. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. Am J Hematol 2003, 72:75-81.
74. Gisslinger H., Rodeghiero F., Ruggeri M., Heis-Vahidi Fard N., Mannhalter C., Papagiannopoulos M., et al. Homocysteine levels in polycythaemia vera and essential thrombocythaemia. Br J Haem 1999, 105:551-555.
75. Harrison C.N., Donohoe S., Carr P., Dave M., Mackie I., Machin S.J. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thr and Haem 2002, 87:802-807.
76. Landolfi R., Marchioli R., Kutti J., Gisslinger H., et al. Efficacy and safety of low dose aspirin in polycythemia vera. NEJM 2004, 350:114-124.
77. Rocca B., Ciabattoni G., Tartaglione R., Cortelazzo S., et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thr Haem 1995, 74:12251230.
78. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc 2003, 78:174-194.
79. Harrison C.N., Campbell P.J., Buck G., Wheatley K., et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005, 353:33-45.
80. Hirsh J., Guyatt G., Albers G.W., Harrington G., Schunemann H.J. Antithrombotic and thrombolytic therapy: American College of Chest Physician. Chest 2008, 133(6 Suppl):110S-112S.